Clobazam Oral Film Granted FDA Approval for Lennox-Gastaut Syndrome


This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome.

Officials with the FDA have approved Aquestive Therapeutics’ clobazam (Sympazan) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older, according to a press release.

Clobazam was previously marketed as Onfi and offered in either tablet or oral suspension formulations. This approval marks the first and only oral film approved by the FDA to treat seizures associated with LGS, according to Aquestive.

Clobazam oral film previously received tentative FDA approval in September based on multiple clinical studies comparing the oral film formulation with Onfi.

LGS is a rare, severe form of epilepsy that typically manifests early in childhood and causes multiple types of seizures and intellectual disability. Often, individuals with the disease have difficulty swallowing pills and large volume suspensions, which can lead to inconsistent dosing and increased burden of care.

“Many LGS patients have a hard time swallowing pills and suspensions. This can make administering medication hard for caregivers,” Christina Sanlnocencio, executive director of the LGS foundation, said in a statement. “We believe Sympazan will be welcomed by patients and caregivers impacted by LGS and searching for treatment solutions.”

FDA Approves Groundbreaking Drug for Treating Rare, Severe Forms of Epilepsy

Clobazam oral film, which was developed following the 505(b)(2) regulatory pathway, was shown to be bioequivalent to clobazam tablets and have comparable safety profiles, according to Aquestive.

The efficacy of clobazam tablets and oral suspension has been established in clinical studies. In a phase 3 study of 238 patients with LGS, data showed that clobazam tablets significantly reduced the frequency of drop seizures compared with baseline by 41% (low dose) to 68% (high dose) versus 12% for placebo.

The latest oral soluble film formulation will be delivered via Aquestive’s proprietary PharmFilm technology, according to the release. The oral film is berry-flavored and offered in 5 mg, 10 mg, and 20 mg dosages.

Aquestive announced they are on track to launch clobazam oral film in November 2018.

This article was originally published at


Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film [news release]. Aquestive Therapeutics’ website. Accessed November 2, 2018.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
Related Content
© 2023 MJH Life Sciences

All rights reserved.